Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS Makes Deeper Dent In Asia Hepatitis Market As Baraclude Moves Toward Blockbuster Status

This article was originally published in PharmAsia News

Executive Summary

BMS’ hepatitis B therapy Baraclude moves toward blockbuster status as company highlights risk of drug resistance with older treatments.

You may also be interested in...

HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex

Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.

Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.

Will World's Largest HCV Population Have Access To Newest Treatments?

With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts